Tirzepatide vs semaglutide: what the head-to-head trial actually showed

For years, comparing the two dominant weight-loss drugs meant comparing separate trials with different populations — a statistical sin everyone committed anyway. Then Eli Lilly funded the comparison directly. SURMOUNT-5 randomized people to tirzepatide or semaglutide and let the drugs fight it out. Here is what happened, and what it should and shouldn't change about your decision.

The two drugs, in one paragraph each

Semaglutide is a GLP-1 receptor agonist: it mimics glucagon-like peptide-1, a gut hormone that slows gastric emptying, increases satiety signaling in the brain, and improves insulin response. It is sold as Ozempic (type 2 diabetes), Wegovy (chronic weight management, 2.4 mg weekly), and Rybelsus (an oral tablet for diabetes). In the STEP 1 trial, published in the New England Journal of Medicine in 2021, adults without diabetes on 2.4 mg weekly lost an average of 14.9% of body weight over 68 weeks, against 2.4% on placebo.

Tirzepatide adds a second mechanism. It is a dual agonist of both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, and the GIP activity appears to amplify both metabolic effects and tolerability at high GLP-1 doses. It is sold as Mounjaro (diabetes) and Zepbound (weight management). In SURMOUNT-1 (NEJM, 2022), the 15 mg weekly dose produced an average 20.9% weight loss over 72 weeks, with 3.1% on placebo; over half of participants on the top dose lost at least a fifth of their body weight — bariatric-surgery territory from a weekly injection.

SURMOUNT-5: the direct comparison

Cross-trial comparisons of those numbers were always shaky — different durations, different baselines, different eras of obesity care. SURMOUNT-5, published in NEJM in 2025, resolved it: roughly 750 adults with obesity and without diabetes, randomized open-label to maximum-tolerated tirzepatide (10 or 15 mg) or maximum-tolerated semaglutide (1.7 or 2.4 mg) for 72 weeks.

The gap was consistent across prespecified thresholds: more tirzepatide participants cleared 10%, 15%, 20%, and 25% loss. Gastrointestinal side effects — nausea, constipation, diarrhea — were the most common adverse events in both arms and occurred at broadly similar rates, mostly mild-to-moderate and concentrated during dose escalation. Discontinuation for adverse events was uncommon in both groups. In short: on average, tirzepatide produced meaningfully more weight loss without an obvious tolerability price.

Three honest caveats before you conclude "tirzepatide wins"

First, averages are not individuals. Distributions overlap substantially. A meaningful minority of semaglutide users out-lose the median tirzepatide user, and non-response exists with both drugs (roughly one in ten to one in seven participants in the big trials lost under 5%). If semaglutide is working for you, SURMOUNT-5 is not, by itself, a reason to switch.

Second, semaglutide holds the strongest outcomes evidence beyond weight. The SELECT trial (NEJM, 2023) showed semaglutide 2.4 mg cut major adverse cardiovascular events by 20% in people with established cardiovascular disease and overweight/obesity — an FDA-labeled indication. Semaglutide also carries data and labeling wins in chronic kidney disease (the FLOW trial) and, more recently, in metabolic liver disease. Tirzepatide has impressive cardiometabolic data of its own — including the first drug approval for obstructive sleep apnea in obesity (Zepbound, December 2024) and strong diabetes results across the SURPASS program, where 15 mg tirzepatide beat 1 mg semaglutide on A1c reduction (−2.3 vs −1.86 percentage points in SURPASS-2) — but semaglutide's hard cardiovascular endpoint remains the benchmark. If your primary risk is a heart attack rather than a number on a scale, that matters.

Third, SURMOUNT-5 was open-label and Lilly-funded. Open-label design was hard to avoid (the pens look different), and the objective endpoint limits bias, but it is right to hold sponsor-funded head-to-heads to a "confirmed until contradicted" standard rather than treating them as scripture.

Cost changes the calculus more than the trial does

At U.S. list prices — historically in the $1,000–$1,350/month range for brand pens before insurance — a 6.5-point efficacy gap can be worth it. But real decisions happen at real prices: manufacturer-direct cash programs for brand vials and pens have generally landed in the $250–$500/month band across 2025–2026 (verify the current figure — these programs changed repeatedly), insurance formularies increasingly prefer one drug over the other (in 2025 the largest U.S. pharmacy benefit manager made Wegovy its preferred GLP-1 for weight loss, dropping Zepbound from its standard list), and telehealth pricing for compounded or program-based access commonly runs $119–$399/month depending on drug and plan — see our pricing ledger for dated, sourced figures. A drug you can afford for eighteen months beats a stronger drug you abandon in month four, because the weight-maintenance data is unforgiving: in trial extensions, people who stopped therapy regained most of what they lost within a year.

How to actually choose

If maximum average weight loss is the goal, insurance or budget permits, and you have no contraindication, the head-to-head supports tirzepatide first. If you have established cardiovascular disease, semaglutide's SELECT evidence and label argue for it. If your insurance covers exactly one of them, take the covered one — adherence beats potency. If you're cash-pay, run the 12-month all-in numbers, not the first-month teaser; that is the entire reason our ledger normalizes true monthly cost and 12-month total for every provider. And whichever molecule you choose, the delivery format matters: injectable formulations are where all of this trial evidence lives. Oral semaglutide exists in FDA-approved form (Rybelsus, with higher-dose obesity tablets in late-stage regulatory review as of early 2026 — verify current status); FDA-approved oral tirzepatide does not exist at all, which is why we wrote a separate, blunt explainer on "tirzepatide tablets."

Seven profiles, seven defaults

Averages pick winners; patients pick fits. The maximum-loss patient with a clean organ history defaults tirzepatide — SURMOUNT-5's 20.2% versus 13.7% is the cleanest head-to-head verdict in the field. The established-cardiovascular patient defaults semaglutide, whose SELECT result and indication our outcomes review details. The moderate-to-severe sleep apnea patient defaults tirzepatide and its OSA indication — often with the insurance door that indication opens. The kidney-disease-with-diabetes patient and the biopsy-grade MASH patient default semaglutide on FLOW and ESSENCE. The budget-first cash payer defaults to whichever verified program price fits — on our dated ledger, semaglutide's floor ($119/month) undercuts tirzepatide's ($139/month), and a working cheaper therapy beats an unaffordable stronger one. The GI-sensitive patient defaults to slow titration on either molecule rather than to a molecule per se — tolerability differences between the two are modest in trials and individual in practice. And the needle-refuser currently defaults to oral semaglutide at approved doses or a short wait for the pipeline, since tirzepatide has no oral form with human evidence. Seven defaults, all starting points for a clinician conversation rather than endings of one.

On switching between them

The switch question arrives eventually in most long therapies — plateau, coverage change, side effects — and deserves realistic framing. Moving semaglutide-to-tirzepatide after a maximum-dose plateau carries rational upside from the head-to-head gap, with a titration restart and its side-effect reset as the toll; dedicated switch trials remain thin, so expectations belong at "additional loss likely, magnitude individual." Moving tirzepatide-to-semaglutide happens too — formulary forces it more often than physiology does, as the 2025 formulary wars showed — and the honest counsel is that stepping to a lower-average-efficacy agent risks partial regain toward its equilibrium, which is worth pre-empting with the maintenance scaffolding rather than discovering on the scale. In both directions the mechanics matter: no stacking or overlap, a clinician-set conversion point in the titration ladder, and a monitoring plan for the first twelve weeks. The molecules are siblings, not interchangeable parts; switches are treatment decisions, and the good ones are planned like it.

The cost-per-result frame, briefly

One more lens for the undecided: divide the year's cost by the expected result and the leaderboard rearranges by budget. At our verified cash floor, a year of tirzepatide runs $1,668 against a trial-average loss around one-fifth of body weight, while semaglutide runs $1,428 against roughly one-seventh — figures that put the two within shouting distance on dollars-per-percentage-point, with tirzepatide buying more total result and semaglutide a lower total outlay. Insurance scrambles this instantly (a covered Wegovy at a $60 copay beats every cash number on the page), and indications scramble it further, which is why this frame is a tiebreaker for the unconstrained cash payer rather than a universal answer. The durable point survives every scenario: compare therapies by twelve-month all-in cost against realistic expected outcomes — never by advertised monthly price against best-case marketing.